Our management team, board of directors, and scientific advisory board are comprised of accomplished drug hunters and experts in the biotechnology and pharmaceutical industries.
Leadership
-
John G. Houston, Ph.D.,
President and Chief Executive Officer
-
Matthew Batters, J.D.,
General Counsel
-
Jeff Boyle,
Vice President of Investor Relations
-
Angela M. Cacace, Ph.D.,
Senior Vice President, Neuroscience & Platform Biology
-
Sean Cassidy, C.P.A.,
Chief Financial Officer
-
Debbie Chirnomas, M.D., M.P.H.,
Vice President of Oncology Clinical Research
-
John A. Grosso, Ph.D.,
Senior Vice President, R&D Technical Operations
-
Eric Masson, PharmD,
Vice President, Early Clinical Development
-
John Northcott,
Chief Commercial Officer
-
Achal Pashine, M.Sc. Ph.D.,
Vice President of Oncology and Immuno-Oncology Research
-
Ron Peck, M.D.,
Chief Medical Officer
-
Christina Sheil, M.D.,
Vice President, Pharmacovigilance
-
Lisa Sinclair,
SVP, Corporate Operations
-
Larry Snyder, Ph.D.,
Vice President of Medicinal Chemistry
-
Ian Taylor, Ph.D.,
Chief Scientific Officer
-
Randy Teel, Ph.D.,
Senior Vice President, Corporate and Business Development
-
Kimberly Wehger,
Vice President, Information Technology & Corporate Projects
-
Steve Weiss,
Senior Vice President, Chief Human Resources Officer